- Dyadic International Inc's DYAI licensee, Epygen Biotech PVD, LTD., has received funding from the Government of India to advance an affordable COVID-19 vaccine candidate through Phase 1 and Phase 2 trials.
- Epygen's COVID-19 vaccine utilizes Dyadic's C1 protein production platform. Epygen Biotech is an Indian Biopharmaceutical company engaged in research and manufacturing therapeutic proteins for critical diseases and novel vaccines.
- Epygen Biotech aims to initially produce 100 million doses per year, at an anticipated price point of approximately $2 per dose, of the potential vaccine, which could be used as the primary and booster against variants.
- Epygen is further planning to raise approximately $26 million for Phase 3.
- Price Action: DYAI shares are down 2.59% at $2.44 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
